BioAtla Statistics
Total Valuation
BioAtla has a market cap or net worth of $25.24 million. The enterprise value is -$6.57 million.
Important Dates
The last earnings date was Tuesday, May 6, 2025, after market close.
| Earnings Date | May 6, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
BioAtla has 58.40 million shares outstanding. The number of shares has increased by 6.70% in one year.
| Current Share Class | 58.40M |
| Shares Outstanding | 58.40M |
| Shares Change (YoY) | +6.70% |
| Shares Change (QoQ) | +17.31% |
| Owned by Insiders (%) | 10.69% |
| Owned by Institutions (%) | 20.72% |
| Float | 39.98M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 2.01 |
| Forward PS | n/a |
| PB Ratio | 46.15 |
| P/TBV Ratio | 46.14 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.35, with a Debt / Equity ratio of 1.01.
| Current Ratio | 2.35 |
| Quick Ratio | 2.02 |
| Debt / Equity | 1.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -246.21% and return on invested capital (ROIC) is -159.03%.
| Return on Equity (ROE) | -246.21% |
| Return on Assets (ROA) | -65.79% |
| Return on Invested Capital (ROIC) | -159.03% |
| Return on Capital Employed (ROCE) | -301.11% |
| Revenue Per Employee | $180,328 |
| Profits Per Employee | -$1.01M |
| Employee Count | 61 |
| Asset Turnover | 0.17 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -84.05% in the last 52 weeks. The beta is 1.00, so BioAtla's price volatility has been similar to the market average.
| Beta (5Y) | 1.00 |
| 52-Week Price Change | -84.05% |
| 50-Day Moving Average | 0.37 |
| 200-Day Moving Average | 1.12 |
| Relative Strength Index (RSI) | 51.79 |
| Average Volume (20 Days) | 552,143 |
Short Selling Information
The latest short interest is 4.30 million, so 7.36% of the outstanding shares have been sold short.
| Short Interest | 4.30M |
| Short Previous Month | 4.06M |
| Short % of Shares Out | 7.36% |
| Short % of Float | 10.75% |
| Short Ratio (days to cover) | 8.17 |
Income Statement
In the last 12 months, BioAtla had revenue of $11.00 million and -$61.88 million in losses. Loss per share was -$1.21.
| Revenue | 11.00M |
| Gross Profit | -52.10M |
| Operating Income | -67.10M |
| Pretax Income | -104.56M |
| Net Income | -61.88M |
| EBITDA | -66.23M |
| EBIT | -67.10M |
| Loss Per Share | -$1.21 |
Full Income StatementBalance Sheet
The company has $32.36 million in cash and $554,000 in debt, giving a net cash position of $31.81 million or $0.54 per share.
| Cash & Cash Equivalents | 32.36M |
| Total Debt | 554,000 |
| Net Cash | 31.81M |
| Net Cash Per Share | $0.54 |
| Equity (Book Value) | 547,000 |
| Book Value Per Share | 0.01 |
| Working Capital | 21.53M |
Full Balance SheetCash Flow
| Operating Cash Flow | -57.40M |
| Capital Expenditures | n/a |
| Free Cash Flow | -57.40M |
| FCF Per Share | -$0.98 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | -610.00% |
| Pretax Margin | -562.51% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |